180 related articles for article (PubMed ID: 10699610)
1. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
Pannek J; Sommerfeld HJ; Bötel U; Senge T
Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
3. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.
Kaplinsky R; Greenfield S; Wan J; Fera M
J Urol; 1996 Aug; 156(2 Pt 2):753-6. PubMed ID: 8683776
[TBL] [Abstract][Full Text] [Related]
4. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
Ferrara P; D'Aleo CM; Tarquini E; Salvatore S; Salvaggio E
BJU Int; 2001 May; 87(7):674-8. PubMed ID: 11350411
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
6. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
Di Stasi SM; Giannantoni A; Vespasiani G; Navarra P; Capelli G; Massoud R; Stephen RL
J Urol; 2001 Feb; 165(2):491-8. PubMed ID: 11176403
[TBL] [Abstract][Full Text] [Related]
7. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
8. Intravesical oxybutynin for spinal cord injury patients.
Szollar SM; Lee SM
Spinal Cord; 1996 May; 34(5):284-7. PubMed ID: 8963976
[TBL] [Abstract][Full Text] [Related]
9. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Haferkamp A; Staehler G; Gerner HJ; Dörsam J
Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396
[TBL] [Abstract][Full Text] [Related]
10. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL
J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.
Saito M; Watanabe T; Tabuchi F; Otsubo K; Satoh K; Miyagawa I
Int J Urol; 2004 Aug; 11(8):592-6. PubMed ID: 15285747
[TBL] [Abstract][Full Text] [Related]
12. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction.
Buyse G; Verpoorten C; Vereecken R; Casaer P
J Urol; 1998 Sep; 160(3 Pt 2):1084-7; discussion 1092. PubMed ID: 9719281
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.
Amark P; Bussman G; Eksborg S
Eur Urol; 1998 Aug; 34(2):148-53. PubMed ID: 9693251
[TBL] [Abstract][Full Text] [Related]
14. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
[TBL] [Abstract][Full Text] [Related]
15. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia.
Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD
J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907
[TBL] [Abstract][Full Text] [Related]
16. Can Oral Fesoterodine Be an Alternative for Intravesical Oxybutynin Instillations in Children with Neuropathic Bladder Dysfunction?
van den Heijkant M; De Coster K; Jansen K; Bogaert G
Urol Int; 2019; 103(2):202-210. PubMed ID: 31117096
[TBL] [Abstract][Full Text] [Related]
17. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia.
Goessl C; Knispel HH; Fiedler U; Härle B; Steffen-Wilke K; Miller K
Urology; 1998 Jan; 51(1):94-8. PubMed ID: 9457296
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury.
George J; Tharion G; Richar J; Macaden AS; Thomas R; Bhattacharji S
ScientificWorldJournal; 2007 Oct; 7():1683-90. PubMed ID: 17982563
[TBL] [Abstract][Full Text] [Related]
19. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
Von Zweigbergk M; Nordin B; Jonsson S
Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D
J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
